PLK1 and breast cancer: Therefore, we assessed the efficacy of the PLK1 inhibitor volasertib (BI 6727)8 in the HBCx-137 PDX, established from an aggressive ER + BC (patient’s clinical history is detailed in Fig. 1d and associated figure’s legend).